It's always good to have friends in high places in Washington. And in the nation's capitol, you can always buy new ones [1].
In another indication of just how important the Medicare market is for biopharma companies, Abiomed revealed that it had paid the influential lobbying group Barbour Griffith & Rogers $100,000 in the first half of this year to lobby Congress and HHS on issues related to Medicare reimbursement and regulatory approval.
- read the Boston Globe report [2]
ALSO: Coincidentally, Abiomed also announced that the FDA has OK'd a new study of a system designed to provide blood flow to patients undergoing surgery. Release [3]
Related Articles:
Amgen ups lobbying efforts. Report [1]
Biomedical researchers lobby against funding cuts. Report [4]
Bay area biotechs plan new lobbying strategy. Report [5]
Crawford signs on as Washington lobbyist. Report [6]
Links:
[1] http://www.fiercebiotech.com/story/amgen-ups-lobbying-efforts/2007-08-17
[2] http://www.boston.com/news/local/massachusetts/articles/2007/08/29/abiomed_paid_lobbyist_100000/
[3] http://www.fiercebiotech.com/press-releases/press-release-abiomed-receives-conditional-fda-approval-impella-2-5-pivotal-study-150
[4] http://www.fiercebioresearcher.com/story/biomedical-researchers-lobby-against-funding-cuts/2007-05-29?utm_source=related&utm_medium=internal
[5] http://www.fiercebiotech.com/story/bay-area-biotechs-plan-new-lobbying-strategy/2006-02-07
[6] http://www.fiercebiotech.com/story/crawford-signs-on-as-washington-lobbyist/2006-02-08